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Abstract
Wilms tumors (WTs) have a complex etiology, dis-
playing genetic and epigenetic changes, including loss
of imprinting (LOI) and tumor suppressor gene silenc-
ing. To identify new regions of epigenetic perturba-
tion in WTs, we screened kidney and tumor DNA using
CpG island (CGI) tags associated with cancer-specific
DNA methylation changes. One such tag corresponded
to a paralog of the glioma pathogenesis–related 1/
related to testis-specific, vespid, and pathogenesis pro-
teins 1 (GLIPR1/RTVP-1) gene, previously reported to
be a tumor-suppressor gene silenced by hypermethyl-
ation in prostate cancer. Here we report methylation
analysis of the GLIPR1/RTVP-1 gene in WTs and nor-
mal fetal and pediatric kidneys. Hypomethylation of
the GLIPR1/RTVP-1 5V-region in WTs relative to normal
tissue is observed in 21/24 (87.5%) of WTs analyzed.
Quantitative analysis of GLIPR1/RTVP-1 expression in
24 WTs showed elevated transcript levels in 16/24 WTs
(67%), with 12 WTs displaying in excess of 20-fold
overexpression relative to fetal kidney (FK) control
samples. Immunohistochemical analysis of FK and WT
corroborates the RNA expression data and reveals
high GLIPR1/RTVP-1 in WT blastemal cells together
with variable levels in stromal and epithelial com-
ponents. Hypomethylation is also evident in the WT
precursor lesions and nephrogenic rests (NRs), sup-
porting a role for GLIPR1/RTVP-1 deregulation early in
Wilms tumorigenesis. Our data show that, in addition
to gene dosage changes arising from LOI and hyper-
methylation-induced gene silencing, gene activation re-
sulting from hypomethylation is also prevalent in WTs.
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Introduction
Wilms tumor (WT) is the most common solid tumor of childhood
and represents a paradigm for tumorigenesis resulting from
disrupted development [1]. Germline defects of chromosome
11p13 in Wilms tumor aniridia genitourinary abnormalities, and
mental retardation (WAGR) signposted the identification of the
tumor-suppressor geneWT1 at this locus [2,3], which has sub-
sequently been shown to have loss of function mutations in 5%
to 10% of sporadic WTs [4]. More recently, a gene on chromo-
some Xq11, referred to as WTX, has been shown to be inac-
tivated in about a third of WTs [5], but for a large proportion of
WTs the etiology is undefined.
In addition to genetic events, WT development has been
closely linked with epigenetic disturbance, and the phenome-
non of loss of imprinting (LOI) was first demonstrated for the
IGF2 gene in WTs [6,7], and has subsequently been shown in
a wide spectrum of other cancers [8]. In common with many
other cancers, WTs also display two-hit epigenetic gene silenc-
ing, i.e., aberrant hypermethylation of tumor-suppressor gene
5V-CpG islands (CGI); examples include RASSF1A (in 42% of
tumors) [9],MCJ (90%), TNFRSF12 (65%) [10], CASP8 (43%)
and MGMT (30%) [11], and SLIT2 (38%) [12].
We have also demonstrated WT-specific hypomethylation
occurring at the WT1 antisense regulatory region (WT1 ARR)
associated with LOI and the increased expression of a putative
regulatory RNA, WT1-AS [13], and an alternative coding tran-
script, AWT1 [14]. Hypomethylation occurs in a CCCTC binding
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factor (CTCF)-binding region and is apparent in nephro-
genic rests (NRs), suggesting an early impairment of methyla-
tion which would normally accompany kidney development,
followed by extensive demethylation during expansion of the
neoplastic rest and WT [15]. However, although genome-
wide hypomethylation has long been known to be a common
feature of all cancers [16], examples of genes that are ac-
tivated by hypomethylation are very scarce compared with
genes shown to be silenced by hypermethylation [17,18].
Examples of genes reportedly activated by hypomethylation
include MN/CA9 in renal cell carcinoma [19], R-RAS in gas-
tric cancers [20], PAX2 in endometrial carcinomas [21], and
SNCG in a variety of adult cancers [22]. With recent ge-
nome analyses suggesting that methylation of CGIs in normal
tissue may be more common than previously thought [23],
many more genes may be deregulated by hypomethylation
in cancer.
In screens for breast cancer–specific methylation changes
using arrayed CGIs, a number of CGI tags were identified as
being hypermethylated in breast cancer cell lines and tumor
tissues. One such tag, referred to as HBC-2 [24], was found
to correspond to the WT1 ARR that we showed to undergo
WT-specific hypomethylation [13]. To identify novel epigenetic
changes in WTs, we assessed other CGI tags identified in the
breast cancer studies and evaluated the methylation of the
corresponding genomic loci. One tag (HBC-1) corresponded
to an uncharacterized paralog of the glioma pathogenesis–
related 1/related to testis-specific, vespid, and pathogenesis
proteins 1 (GLIPR1/RTVP-1) gene, a proapoptotic p53 target
gene [25]. Although it was originally identified as a gene over-
expressed in gliomas where it has recently been reported to
exert antiapoptotic functions [26,27], epigenetic silencing of
GLIPR1/RTVP-1 was demonstrated in prostate cancer, impli-
cating it as a putative tumor-suppressor gene [28]. We were
therefore prompted to evaluate its epigenetic status in WTs
relative to normal fetal and pediatric kidney samples. We pre-
sent data showing that, contrary to the hypermethylation evi-
dent in prostate cancers, GLIPR1/RTVP-1 hypomethylation
is prevalent in a high percentage of WTs. High expression
of GLIPR1/RTVP-1 is frequently observed in conjunction with
hypomethylation. Hypomethylation is also apparent inWT pre-
cursor lesions, suggesting it as an early contributory event in
Wilms tumorigenesis. Our data suggest that gene activation
accompanying hypomethylation of non-imprinted genes is a




All tissues were acquired with appropriate ethical approval
as snap frozen samples from the Bristol Children’s Hospital
and the University of Heidelberg Children’s Hospital. WT tis-
sues ranged from stage I to stage V and were obtained along
with adjacent histologically normal kidney (NK) and,where avail-
able, NRs. Fetal kidney (FK) samples were from 19 to 31 weeks
of gestation. A clear cell sarcomaof the kidney (CCSK)was also
obtained along with adjacent histologically normal kidney.
Details of clinical samples are given in Table 1. Extraction of
total cellular RNAwas performed as previously described [29].
DNA were evaluated for loss of heterozygosity using micro-
satellite markers D12S1052 and D12S869 on chromosome
12q21. No gains or losses were apparent in informative sam-
Table 1. Summary of Clinical and Molecular Features of Wilms Tumors Analyzed.
WT Sex Tumor/Age
at Diagnosis (months)
Stage/Histology Outcome WT1 Mutation Details 11p13 LOH 11p15 LOH 16q LOH
8 M UL/67 III/tr, fh A N LOH LOH HT
24 M UL/13 I/tr, s, fh A 5-bp deletion in exon 7 LOH LOH HT
28 F UL/19 I/b, fh A N HT LOH HT
29 F UL/9 II/b, e, fh R 1991, D 1991 N HT HT HT
48 F UL/44 I/b, s, fh A HT HT HT
54 F BL/19 V A 5-bp insertion exon 1: GERMLINE LOH LOH HT
56 F UL/50 II/b, s A LOH HT LOH
57 F UL/48 III A HT HT HT
61 F UL/43 II A LOH LOH HT
62 F BL/39 V/tr R 1995, D 1996 HT HT LOH
63 F UL/35 II/tr, fh R 1996, A LOH LOH LOH
65 F BL/56 V/tr R 1996, A HT HT LOH(L) N(R)
69 F UL/43 II/fh A HT HT HT
71 M UL/47 IV A HT HT LOH
72 M /105 HT HT HT
77 M UL/29 II A LOH LOH HT
83 F UL/6 III/e, fh R 2000, A
84 F UL/120 IV/tr, fh D 2000 HT HT LOH
85 M UL/19 I/tr, fh R 2001, A HT ni HT
HD9 M UL/30 IA/s A 4 bp insertion exon 6 HT HT
HD14 M UL/12 I/s A 7 bp deletion in exon 1b: GERMLINE LOH LOH
HD2 F BL/15 V/s A 26 bp deletion in exon 1b: GERMLINE LOH HT
HD1 F BL/7 V/s A C–A transition in exon 7: GERMLINE LOH HT
HD13 F UL/8 III/s A 16-bp deletion in exon 7 LOH
ANS2 M UL/21 II/tr A 1700-kb deletion HEM
F, female; M, male; UL, unilateral; BL, bilateral; fh, favorable histology; tr, triphasic; b, blastemal predominant; e, epithelial predominant; s, stromal predominant;
A, alive; R, relapsed; D, died; N, no; LOH, loss of heterozygosity; HT, heterozygous; HEM, constitutionally hemizygous; blank spaces, not done; ni, noninformative.
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ples and, therefore, hypomethylation was distinguishable
from allele loss.
Methylation Analyses
The HBC-1 sequence (see Figure 1) was analyzed using
BLAST (www.ncbi.nlm.nih.co.uk/BLAST) and was found to
align with the 5V-end of the GLIPR1L1 gene, close to the
GLIPR1/RTVP-1 gene on chromosome 12q21 (see Figure 1A).
For combined bisulfite and restriction analysis (COBRA)
[30], genomic DNA were converted using the EZ DNA
Methylation-Gold conversion kit (Zymo Research, Orange,
CA) according to the manufacturer’s instructions. CpGenome
universally methylated DNA (Chemicon, Billerica, MA) was
used as a positive control for COBRA assays and the follow-
ing primer and digest combinations were used.
Products were separated by agarose gel electrophoresis
and band intensities were quantified using ImageJ software
(http:rsb.info.nih.gov/ij/). Bisulfite sequencing used the CO-
BRA primers and Hotstart plus Taq (Qiagen, Crawley, UK).
Polymerase chain reaction (PCR) products were cloned into
pGEM TEasy (Promega, Southampton, UK) or TOPOTAKit
(Invitrogen, Paisley, UK) and positive clones were sequenced.
To generate a larger probe for GLIPR1L1 by Southern
blot analysis, the HBC-1 tag was used to screen a genomic
library as described previously [31]. A plasmid subclone des-
ignated pEBE1.4 was generated from a positive phage clone
and its insert was excised and radiolabeled for Southern blot
analysis with genomic DNA digested with SacII, EcoRI,
and BamHI. Experimental conditions were as previously
described [13].
Reverse Transcriptase–Polymerase Chain Reaction
(RT-PCR) Analysis
Total RNA (1 mg) was reverse-transcribed with oligo(dT)20
at 60jC for 60 minutes using the ThermoScript RT-PCR Sys-
tem (Invitrogen) according to the manufacturer’s instructions.
RNA complementary to the cDNA was removed by incubat-
ing with 2 URNaseH at 37jC for 20minutes. cDNAwas ampli-
fied using 5 ml of a 1:10 dilution of the reverse transcribed
cDNA in a 25-ml PCR reaction containing 0.5 U SuperTaq (HT
Biotechnology, Cambridge, UK), 0.2 mM each deoxyribonu-
cleotide triphosphate (Sigma, Poole, UK) and 0.3 mM forward
and reverse primers. For expression analyses, the following
primerswere used:GLIPR1, forward primer (5V–AGGCTCCAT-




HPRT1, forward primer (5V–CTTGCTGGTGAAAAGGACC-
CC–3V) and reverse primer (5V–GTCAAGGGCATATCCTAC-
AAC–3V). Thermal cycling consisted of an initial denaturation
step of 94jC for 4 minutes and was followed by 35 cycles
with denaturation at 94jC for 30 seconds, annealing at 57jC
for 30 seconds, and elongation at 72jC for 1minute and 30 sec-
onds. RT-PCR products were analyzed on a 1% agarose gel.
ForGLIPR1L1, gels were alkali-blotted onto Hybond-N+ mem-
brane and hybridized with 32P-labeled cDNA probes.
Figure 1. The GLIPR1/RTVP-1 locus. (A) Schematic of the GLIPR1/RTVP-1 locus on chromosome 12q21. The top line shows the GLIPR1/RTVP-1 paralog cluster
and CpG islands in this region (hatched boxes). (B) GLIPR1/RTVP-1 methylation analysis. The sequence of the GLIPR1/RTVP-1 upstream region is shown with
CpGs in bold and exon 1 is shaded. Sites converted to TaqI sequences for COBRA are boxed, and the translational start site and COBRA primers are underlined.
Restriction fragments generated by COBRA are shown below, with CpG sites analyzable by COBRA shown as open circles. Other CpGs are shown as closed
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Comparative Quantitative Real-Time PCR
Real-time PCR was performed using the Stratagene
MX3000P QPCR System (La Jolla, CA) along with the Plat-
inum SYBR green qPCR SuperMix-UDG (Invitrogen). Reac-
tions volumes of 20 ml contained 10 ml of Platinum SYBR
green qPCR SuperMix-UDG (Invitrogen, Paisley, UK), 50 nM
ROX reference dye, 0.2 mM forward primer, 0.2 mM reverse
primer, and 0.5 ml of cDNA template. Primers were: GLIPR1,
forward primer (5V–GCGTTCGAATCCATAACAAGTTCC–3V)
and reverse primer (5V–GGTGGCTTCAGCCGTGTATTAT-
GTG–3V); GLIPR1L1, forward primer (5V–AATCCCATCCAT-
CACTGACCCACA–3V) and reverse primer (5V–GCCCAT-
GCTTTAGCCATCTTTGCT–3V); and MCJ, forward primer
(5V–ACCAGCAGGGACTGGTAAGAAGTT–3V) and reverse
primer (5V–TTCCAGATCCGAAATGCGTAGCGA–3V). Ther-
mal cycling consisted of an initial incubation step of 50jC for
2 minutes and then a denaturation step of 95jC for 10 min-
utes. This was followed by 40 cycles of denaturation at 95jC
for 15 seconds, annealing at 55jC for 30 seconds, and elon-
gation at 72jC for 30 seconds. A final dissociation curve con-
sisting of denaturation at 95jC for 1minute, annealing at 55jC
for 30 seconds, and elongation at 95jC for 30 seconds was
used to identify a single correctly sized product. Gene expres-
sion was quantified by comparative Ct method, normalizing
values to the housekeeping gene TBP orGAPDH and relative
to a calibrator. Expression analysis for TBP was performed
using forward primer (5V–GCCCGAAACGCCGAATAT–3V)
and reverse primer (5V–CCGTGGTTCGTGGCTCTCT–3V)
and for GAPDH it was performed using forward primer (5V–
GTTCGACAGTCAGCCGCATC–3V) and reverse primer (5V–
GGAATTTGCCATGGGTGGA–3V). To ensure experimental
accuracy, all reactions were performed in duplicate.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections for FK and
WT were sectioned at 6 mm on poly-L-lysine-coated slides.
Immunostaining was carried out as previously reported [28]
with the following modifications. Briefly, sections were rehy-
drated and blocked for endogenous peroxidase activity in
3% H2O2 in methanol. Following microwave antigen retrieval
using citrate buffer, samples were blocked with 5% normal
goat serum. An additional avidin/biotin blocking step was
used to eliminate further endogenous biotin (Dako, Ely, UK).
RTVP-1 primary antibody (a kind gift from Dr. T. Thompson,
Baylor College of Medicine, TX) was diluted 1 in 2000 in
phosphate-buffered saline and was incubated at room tem-
perature for 4 hours. The secondary antibody was biotin-
ylated goat anti-rabbit followed by horseradish peroxidase
streptavidin (Dako). Visualization was with the DAB–sub-
strate chromogen system (Dako).
5-Aza-2 V-Deoxycytidine (AZA) Treatment
Anaplastic WT-derived cell lines 17.94 (Brown, unpub-
lished observations) and WiT49 were treated 24 hours after
seeding with 5 mM of the DNA methylation inhibitor AZA
(Sigma). Treatment was repeated after a further 24-hour
period, and again 48 hours after that. Cells were harvested
after a final 24-hour incubation period.
Results
Hypomethylation of GLIPR1/RTVP-1 in WTs
The CGI tag, HBC-1, which undergoes tumor-specific
hypermethylation in breast tumors [24], was found to corre-
spond to the 5V-end of the GLIPR1L1 gene. Methylation
changes for this gene are described briefly below, but as
nothing is known of GLIPR1L1 function, and expression of
this gene is low or absent in renal samples, it was not fo-
cused on. TheGLIPR1L1 gene is located in a paralog cluster
on chromosome 12q21 (see Figure 1A) [32], which includes
GLIPR1L2 and GLIPR1/RTVP-1. As GLIPR1/RTVP-1 has
been reported to have pro- and antiapoptotic activities [25,27],
and the gene was silenced by hypermethylation in cancer
[28], it was analyzed in detail.
We assessed methylation of theGLIPR1/RTVP-1 gene in
WTs using COBRA across CpGs shown to affect expression
(sites I, K, and L according to Ren et al. [28]) (see Figure 1B).
Whereas matched FKs (n = 3) and NKs (n = 17) exhibited
considerable methylation of the GLIPR1/RTVP-1 gene 5V-
region, 21/24 WTs (87.5%) displayed extensive hypometh-
ylation (see Figure 2A). One of the three FK samples assayed
is shown, and one of the three WTs without hypomethylation
(sample 61). TriphasicWTs, blastemal-richWTs, and stromal
predominant WTs (see Table 1) were all represented in the
analysis and showed similar hypomethylation. We also ob-
served a similar pattern in CCSK (sample 23). As COBRA en-
compasses only three CpG dinucleotides, we further assessed
methylation changes using bisulfite sequencing. This confirmed
that methylation was widespread in FK and NK at CpGs F–L
(see Figure 1B), but virtually absent in WT (see Figure 2B).
Overexpression of GLIPR1/RTVP-1 in WTs
We analyzed 5 FK RNA, 18 NK RNA, and 24 WTs for
GLIPR1/RTVP-1 transcripts by quantitative RT-PCR, and
representative results are shown in Figure 3A. Six NK sam-
ples (five fetal and one pediatric kidney) are shown on the left
of the histogram, followed by six matched NK/WT pairs, and
six WTs with characterized WT1 mutations on the right [33].
Of the latter ANS2 had triphasic histology and the remainder
were stromal predominant WTs (see Table 1). Five of the six
tumors with matched NK showed GLIPR1/RTVP-1 expres-
sion levels elevated 17- to 150-fold relative to 19-week-old
FK, and the stromal predominant WTs showed 11- to 40-fold
increases. Interestingly, tumor 62, despite exhibiting clear hy-
pomethylation (see Figure 2A), expressed approximately 80%
less GLIPR1/RTVP-1 than the matched NK, the only tumor
to show this pattern. This tumor is an anaplastic WT with a
p53mutation, and the loweredGLIPR1/RTVP-1 expression in
this sample is consistent with p53 being an activator of the
GLIPR1/RTVP-1 gene transcription [25]. Of 16 WTs where
adjacent NKwas also assessed, this was the only sample with
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reduced expression in the tumor. Of the remainder, 13/16WTs
had higher expression than NKs and 2 had equivalent levels.
The CCSK displaying hypomethylation (sample 23; see Fig-
ure 2A) did not show marked overexpression compared to its
matched NK (2.7-fold vs 4.1-fold). A plot of all kidney and WT
samples analyzed is shown in Figure 3B and median expres-
sion levels for the three sample sets were 4.8 (FKs), 3.5
(NKs), and 21.9 (WTs). Sixteen of 24WTs expressedGLIPR1/
RTVP-1 transcripts levels higher than the FK median. As pre-
viously shown [28], demethylation induced by treating cultured
cells with AZA was found to increase GLIPR1/RTVP-1 ex-
pression (Figure 3C).
Wilms tumors arise during embryonic kidney develop-
ment and it is therefore imperative to evaluate molecular
changes inWTs relative to FK. Expression of GLIPR1/RTVP-
1 protein was assessed in these tissues using an anti–
GLIPR1/RTVP-1 antibody previously used in analysis of
prostate cancers [28]. Immunohistochemical staining of FK
sections demonstrated nuclear expression of GLIPR1/RTVP-1
in epithelial cells of the primitive glomeruli and fainter expres-
sion in the blastema at the kidney edge, together with weak
cytoplasmic staining in primitive tubules (see Figure 4). In a
triphasic WT, GLIPR1/RTVP-1 was strongly expressed in
blastemal cells, mainly in the cytoplasm. Staining in epithelial
and stromal elements can be observed but was weaker or
absent compared to the blastemal cells. Crucially, the tumor
blastemal cells clearly expressed higher GLIPR1/RTVP-1 than
the FK blastemal cells. Together with the methylation analysis,
our RNA and protein expression data strongly suggests that
GLIPR1/RTVP-1 is induced by hypomethylation in WTs.
Hypomethylation Is an Early Event in Wilms Tumorigenesis
The preceding analyses strongly suggests that hypo-
methylation of specific genes in WTs can lead to their over-
expression. However, it is uncertain whether such changes
are a cause or consequence of tumor development. We
therefore assessed the methylation status of GLIPR1/
RTVP-1 in WT precursor lesions and NRs. Figure 5 shows
COBRA of a NK, WT, and NR set (patient 65), together with a
second rest (patient 62). Both left and right tumors from
patient 65 showed hypomethylation, and the NR showed
partial hypomethylation (see Figure 5, A and B). A second
NR from a different patient (62) showed comparable meth-
ylation to the patient 65 rest. These results are indicative of
an early progressive decrease in gene-specific methylation
during Wilms tumorigenesis or an expansion of cells with
GLIPR1/RTVP-1 hypomethylation.
GLIPR1/RTVP-1 Methylation Changes Are Specific
and Not Regional
We used the HBC-1 tag to subclone a single-copy probe
spanning the GLIPR1L1 5V-end to assess DNA methylation
at a region proximal to GLIPR1/RTVP-1 (see Figure 6A). As
shown in Figure 6C, two major bands were apparent in
Figure 2. Methylation analysis of GLIPR1/RTVP-1. (A) COBRA of kidneys and WTs. FK, fetal kidney; NK, normal kidney; CS, clear cell sarcoma of the kidney; C,
control methylated DNA; (), undigested; (+), digested. Densitometric analysis of methylation is shown as a histogram, where hypomethylated bands are
expressed as a percentage of all bands, black fill indicating percentage methylation, and no fill indicating hypomethylation. (B) Bisulfite sequencing of kidney and
tumor DNA. Filled lollipops represent methylated CpG dinucleotides and open lollipops represent unmethylated CpGs.
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Figure 3. Expression analyses of GLIPR1/RTVP-1. (A) Histogram showing GLIPR1/RTVP-1 mRNA expression in selected Wilms tumors relative to FK samples
and matched NKs. Values are expressed as fold changes relative to a 19-week-old FK. (B) Scatter plot of quantitative RT-PCR analysis of control and tumor
samples. The median value for each sample type is shown by the dashed line. (C) Correlation of AZA-induced methylation changes with altered gene expression.
Histograms show relative changes in transcript levels and the panel above confirms demethylation by COBRA analysis: (), undigested; (+), digested.
Figure 4. Immunohistochemical analysis of GLIPR1/RTVP-1 protein expression. A 16-week-old FK and a triphasic WT are shown at low (left) and high
magnification (right), with negative controls shown in the insets. bl, blastema; ep, epithelial cells; pg, primitive glomerulus; pt, primitive tubules; st, stroma. Nuclear
staining in epithelial cells in FK and cytoplasmic staining in WT blastemal cells is arrowed in high-magnification pictures.
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normal tissue DNA, corresponding in size to fragments di-
gested (975 bp) and undigested (1410 bp) at the SacII site
within GLIPR1L1 exon 1. Figure 6C (top panel) shows that
7/15 WTs examined had hypomethylation relative to the ap-
parent differential methylation observed with normal DNA. A
further 3/15WTs showed no changes relative to their adjacent
NK (patients 83, 86, and 69) and 5/15 of patient samples an-
alyzed displayed apparent hypermethylation of GLIPR1L1.
The Southern blot analysis of normal tissues and WTs repre-
senting hyper- and hypomethylated subsets was confirmed by
bisulfite sequencing (see Figure 6D). Methylation in normal
tissues was highly restricted in the region of the SacII site and
reflected the pattern of differential methylation observed by
Southern blot analysis. One of the panel of tumors showing
hypomethylation in Figure 6C, WT72, showed virtually no
methylation, whereas bisulfite sequencing of WT81 was in
accord with Southern blot data, displaying increased methyl-
ation relative to normal tissues. Thus, in contrast to GLIPR1/
RTVP-1, GLIPR1L1 appeared consistently and differentially
methylated in normal tissues and displayed very variable
methylation patterns in WTs. Importantly, the epigenetic het-
erogeneity at this locus suggests that the high frequency of
hypomethylation observed for GLIPR1/RTVP-1 is not merely
a reflection of locus or cell type–specific methylation changes,
as many samples that show hypomethylation at GLIPR1/
RTVP-1 do not show hypomethylation atGLIPR1L1 (compare
samples 24, 61, 63, 69, 83, and 85 in Figures 2A and 6C). We
assessed GLIPR1L1 transcript levels in kidney and WT
samples and, although expression was too low to detect by
RT-PCR, very low levels could be detected after Southern blot
analysis and hybridization with radioactive probes in six
Figure 6.Methylation and expression analysis of GLIPR1L1. (A) Themethylation assay contingent onSacII methylation status is shown with possible fragments and CpG
distribution. (B) Sequence of the GLIPR1L1 upstream region. The sequence of the HBC-1 tag is between the double-underlined bases, CpGs are shown in bold, and exon
1 is shaded. The SacII site is boxed, and primer regions for COBRA are underlined. (C) Southern blots showing WTs with hypomethylation (top panel) and hyper-
methylation (middle panel). Densitometric quantification for hypomethylation is shown as a histogram, where 50% denotes equal intensities of 1410- and 975-bp bands
and 0% denotes complete absence of the 1410-bp band. The bottom panel showsWTs and fetal DNA with no change. (D) Bisulfite sequencing of kidney and tumor DNA.
Filled lollipops represent methylated CpG dinucleotides and open lollipops represent unmethylated CpGs. The black bars mark the two CpG residues within the SacII site
used in Southern blot analysis. (E) GLIPR1L1 RT-PCR analysis shown with methylation summary for assayed samples and HPRT-1 as housekeeping control.
Figure 5. Hypomethylation in NRs and bilateral Wilms tumor. (A) GLIPR1
COBRA of matched DNA from patient 65 and an additional NR from patient
62. WTL, left Wilms tumor; WTR, right Wilms tumor; NR, nephrogenic rest.
(B) Percentage histogram of densitometric estimation of methylation (black),
partial hypomethylation (gray), and complete hypomethylation (white).
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patient samples (see Figure 6E ). All other samples were
negative. Although WTs appear to express higher levels of
GLIPR1L1 than kidney controls, the expression did not cor-
relate with methylation status, as samples with tumor hyper-
methylation (61, 81, and 85) and hypomethylation (28, 57, and
72) had detectable GLIPR1L1.
Discussion
The analysis of tumor-suppressor gene silencing in can-
cer cells is a major focus of contemporary cancer research.
However, there is increasing evidence that gene activation
associated with hypomethylation is involved in cancer. Exam-
ples include PAX2 activation in endometrial carcinomas [21]
and SNCG activation in a wide variety of human cancers [22].
In this report, we show for the first time that hypomethylation-
associated gene activation of nonimprinted genes is found in
WT, with the GLIPR1/RTVP-1 gene displaying deregulated
expression in tumors relative to normal fetal and pediatric
kidney. Furthermore, we demonstrate that altered methylation
is detectable in WT precursor lesions, suggesting that these
changes occur early and may contribute to tumorigenesis.
Our methylation analysis of GLIPR1/RTVP-1 reveals re-
markably frequent tumor-specific hypomethylation of the gene,
apparent in 87.5% of WTs (n = 24). By way of comparison, R-
RAS analysis showed partial hypomethylation in 3/5 primary
gastric [20]. Also, whereas a large study of the SNCG in adult
cancers demonstrated hypomethylation of this gene in all tu-
mors (n = 20 per tumor), hypomethylation was also observed
in 30% of normal adjacent tissue [22], in contrast to our find-
ings of highly tumor-specific hypomethylation. GLIPR1/
RTVP-1 has already been shown to be epigenetically altered
(hypermethylated) in prostate cancer, and it will clearly be of
great interest to evaluate its epigenetic status in other cancers.
GLIPR1/RTVP-1 has been shown to be a p53-regulated
proapoptotic tumor-suppressor gene undergoing epigenetic
silencing in prostate cancer [25,28]. However, in glioma cells,
GLIPR1/RTVP-1 expression is high [26,27]. Quantitative
mRNA analysis revealed that GLIPR1/RTVP-1 levels were
approximately 3-fold higher in low-grade astrocytomas com-
pared to normal brain, with glioblastomas being 8-fold higher.
Strikingly, our expression analysis of WTs shows that over
half express mRNA levels in excess of 20-fold relative to FK,
with some even exceeding 100-fold. In all, 16 WTs showed
elevated expression levels, whereas 8 did not; of the latter,
2 displayed no hypomethylation, and 1 tumor had a p53 mu-
tation. Hence, for 5 of 24 tumors, there was no direct cor-
relation between methylation/genetic factors and GLIPR1/
RTVP-1 expression. Similar results have been observed
for other genes undergoing hypomethylation such as SNCG
[22], where approximately 30% of tumors did not show
a methylation/expression correlation. This is likely attribut-
able to the absence or alteration of other cellular proteins
which may be necessary for high-level expression of GLIPR1/
RTVP-1. Concomitant requirement for hypomethylation and
upregulation of the transcription factor early growth response-1
has been reported for heparanase gene overexpression in
prostate [34] and bladder cancers [35].
In glioma cells, theGLIPR1/RTVP-1 protein positively reg-
ulates growth, survival, and invasion. GLIPR1/RTVP-1 over-
expression results in elevated Bcl2, leading to an antiapoptotic
effect, and increases the activity of matrix metalloproteinase-
2, thereby positively regulating the invasive potential of glioma
cells [27]. We also note that the scl-1 gene in Caenorhabditis
elegans, which is homologous to GLIPR1/RTVP-1, has been
shown to encode a regulator of longevity and stress resis-
tance [36]. Our methylation analysis of GLIPR1/RTVP-1 re-
vealed tumor-specific hypomethylation and overexpression
relative to FK and NK in WTs. Although the biologic roles of
GLIPR1/RTVP-1 in WTcells remain to be elucidated, it is plau-
sible that, as in the case of gliomas, GLIPR1/RTVP-1 exerts a
proliferative, prosurvival influence.
Our recent study of epigenetic deregulation of AWT1/
WT1-AS in WTs showed that LOI is an early event in Wilms
tumorigenesis [15]. Hypomethylation of GLIPR1/RTVP-1
is apparent in NRs and in left and right tumors where WT
is bilateral. Although the progressive increase in hypometh-
ylation seen in NRs might be considered to simply reflect
an expansion of oncofetal cells, our previous work argues
against this as methylation at the WT1 ARR in NRs shows
a general increase relative to FK [15]. Therefore, the early
gene-specific hypomethylation reported for GLIPR1/RTVP-1
may contribute to Wilms tumorigenesis, rather than merely
accompanying tumorigenesis. This is supported by our im-
munohistochemical analysis showing that WT blastemal
cells express very high levels of GLIPR1/RTVP-1 compared
to FK blastemal cells. Overexpression of GLIPR1/RTVP-1
in WT may serve as a useful diagnostic marker, although
therapeutic use may be complicated by GLIPR1/RTVP-1
expression seemingly required for NK development
and function.
Our methylation analysis of GLIPR1L1 further supports
the contention that GLIPR1/RTVP-1 methylation changes in
WT are specific and not just regional. Our preliminary anal-
ysis also shows that the GLIPR1L2 gene does not undergo
epigenetic alterations in WT (data not shown). Although
some methylation changes are observed at the GLIPR1L1
gene, they are inconsistent and do not correlate with expres-
sion. Expressions of GLIPR1L1 by Northern blot analysis
(data not shown) and by quantitative RT-PCR [32] show that
it is highly expressed in the testis with little or no expression in
other tissues. This highly restricted expression pattern, together
with the expression shown here in tumors, suggests that
GLIPR1L1 can be considered a cancer–testis gene. Cancer–
testis proteins are only found in a minor subset of cells within
a tumor and it has been suggested that they may serve as a
marker for cancer stem cells [37]. Thus, although GLIPR1L1
expression was very low in WTsamples, it may yet be a valu-
able target for immunotherapy against cancer stem cells.
Finally, given that a recent analysis of the human genome
suggests that methylation of non-CGI upstream regions is
relatively common [23,38], our study underlines the need for
extensive analysis of gene activation by hypomethylation
and emphasizes an important caveat for cancer therapies
using DNA methylation inhibitors, because these may inap-
propriately activate tumor-promoting genes.
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